Novo Nordisk Net Income 2010-2022 | NVO

Novo Nordisk net income from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Novo Nordisk Annual Net Income
(Millions of US $)
2021 $7,598
2020 $6,456
2019 $5,839
2018 $5,906
2017 $5,792
2016 $5,636
2015 $5,187
2014 $4,722
2013 $4,485
2012 $3,703
2011 $3,195
2010 $2,568
2009 $2,017
Novo Nordisk Quarterly Net Income
(Millions of US $)
2022-03-31 $2,143
2021-12-31 $1,665
2021-09-30 $1,922
2021-06-30 $1,965
2021-03-31 $2,046
2020-12-31 $1,512
2020-09-30 $1,617
2020-06-30 $1,569
2020-03-31 $1,757
2019-12-31 $1,285
2019-09-30 $1,519
2019-06-30 $1,445
2019-03-31 $1,590
2018-12-31 $1,066
2018-09-30 $1,410
2018-06-30 $1,656
2018-03-31 $1,775
2017-12-31 $1,320
2017-09-30 $1,544
2017-06-30 $1,472
2017-03-31 $1,456
2016-12-31 $1,253
2016-09-30 $1,470
2016-06-30 $1,514
2016-03-31 $1,398
2015-12-31 $1,204
2015-09-30 $1,250
2015-06-30 $1,236
2015-03-31 $1,497
2014-12-31 $1,093
2014-09-30 $1,157
2014-06-30 $1,285
2014-03-31 $1,186
2013-12-31 $1,107
2013-09-30 $1,139
2013-06-30 $1,180
2013-03-31 $1,059
2012-12-31 $1,005
2012-09-30 $953
2012-06-30 $924
2012-03-31 $822
2011-12-31 $831
2011-09-30 $786
2011-06-30 $798
2011-03-31 $747
2010-12-31 $729
2010-09-30 $668
2010-06-30 $627
2010-03-31 $596
2009-12-31 $460
2009-09-30 $547
2009-06-30 $547
2009-03-31 $480
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $22.397B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $465.705B 17.91
Pfizer (PFE) United States $294.404B 10.27
Eli Lilly (LLY) United States $283.955B 33.50
AbbVie (ABBV) United States $266.851B 11.70
Merck (MRK) United States $236.570B 13.36
Novartis AG (NVS) Switzerland $200.009B 14.40
GlaxoSmithKline (GSK) United Kingdom $113.161B 13.21